Recro Pharma

Societal CDMO, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief.   It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Concert Pharma

Cardiff Oncology

Intellicheck

Veritiv

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second quarter. If you're looking for stocks to hedge your portfolio, these are our Top Shorts for today.

Best Companies To Short As Nasdaq And Tech Stocks Retreat

BIO-key Int.

Cocrystal Pharma

Second Sight Medical Products

EyePoint Pharmaceuticals

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Top Stocks To Short As Dow Jumps Amid Coronavirus Spikes

Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products

Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies

Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher

Recro Pharma, Inc.'s (REPH) CEO Gerri Henwood on Q1 2020 Results - Earnings Call Transcript

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recro Pharma (REPH) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Recro Capitalizing on Strong and Growing CDMO Business

Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets

Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies

Separation of Baudax Bio as Independent Company Expected to be Completed  With Distribution on November 21, 2019

Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q3 2019 Results - Earnings Call Transcript

Recro Pharma (REPH) delivered earnings and revenue surprises of -46.15% and 27.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Recro Pharma (REPH) Reports Q3 Loss, Tops Revenue Estimates

Recro Pharma: FDA Grants Appeal For IV Meloxicam, Adding Value To The Proposed Acute Care Spin-Out

Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request

FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application

Recro Pharma (REPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Excluding the IV meloxicam CRL, Recro Pharma has a strong 2019 with cutting OpEx and moving closer to cash flow positive. However, management is looking to spin-out the acute care segment.

Recro Pharma: Buying Before Acute Care Spin-Out

As of late, it has definitely been a great time to be an investor Recro Pharma.

Will Recro Pharma Continue to Surge Higher?

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q2 2019 Results - Earnings Call Transcript

Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates

Recro Pharma (REPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Affimed

Arrowhead Pharmaceuticals

Incyte

Repligen

Veracyte

Vertex Pharmaceuticals

Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.

7 Top-Rated Biotech Stocks to Invest In Today

DHT Holdings

Flexible Solutions

India Globalization Capital

Sachem Capital

These stocks to buy are low-priced, top quality choices for growth. Here's what you need to know about each.

A-Rated Stocks to Buy Under $10

Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q1 2019 Results - Earnings Call Transcript

Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Recro Pharma (REPH) Reports Q1 Loss, Tops Revenue Estimates

Recro Pharma (REPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recro Pharma (REPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

As of late, it has definitely been a great time to be an investor in Recro Pharma, Inc. (REPH).

News for Recro Pharma Stock (REPH)